Standard BioTools Inc.

LAB

Healthcare

$0.98-0.33%vs prev close

$0.87

$1.72

52W RangeNear 52W Low

+0.04 (+4.30%)Past 1M

Price

Stock Timeline

Institutional Holders

1 Holding · 1 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Andreas HalvorsenViking Global Investors

Maintained

58,651,170

Portfolio Weight

0.2%

Est. Value

$75M

vs Prev Quarter

Maintained

Sold · Q4 2025

Cathie WoodARK Invest

Fully Sold

Portfolio Weight

Prev Holdings

189

Est. Sold Value

$185.92

Holding Period

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

None

Buy

Hold

Analyst Targets

avg.

$1.55

vs Current ▲ +58.8% upside

Current$0.98

Low ~ High$1.35 ~ $1.75

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

TD Cowen

Hold

$1.35

+38.35%

$1.14

Maintain

2025-11-05

Keybanc

Sector Weight

N/A

$1.05

Downgrade

2025-02-27

TD Cowen

Buy

$2.50

+156.20%

$1.96

Maintain

2024-10-31

TD Cowen

Buy

$2.75

+181.82%

$1.42

Maintain

2024-08-01

TD Cowen

Buy

$3.50

+258.68%

$2.71

Upgrade

2024-04-16

1 / 1

Avg Target

$1.55

vs Current ▲ +58.8% upside

None

3 analysts

Buy 1Hold 2

Low $1.35

Current $0.98

High $1.75

Firm	Position	Target	Upside	Close	Action	Date
TD Cowen	Hold	$1.35	+38.35%	$1.14	Maintain	25.11.05
Keybanc	Sector Weight	N/A	N/A	$1.05	Downgrade	25.02.27
TD Cowen	Buy	$2.50	+156.20%	$1.96	Maintain	24.10.31
TD Cowen	Buy	$2.75	+181.82%	$1.42	Maintain	24.08.01
TD Cowen	Buy	$3.50	+258.68%	$2.71	Upgrade	24.04.16

1 / 1

Price Information

Previous Close$0.98

Open$1.00

Day Range$0.95 - $1.00

52-Week Range$0.87 - $1.72

1-Year Change-3.92%

Trading Volume

Volume1,683,613

Avg Volume (3mo)2,552,180

Valuation

Market Cap380.9M

Book Value$1.10

Shares Outstanding390,368,119

Financials

Revenue (TTM)85.3M

Net Income-58,826,000

EPS$-0.15

EBITDA-82,328,000

Profitability

P/E Ratio-

P/B Ratio0.89

Return on Equity (ROE)-13.13%

Return on Assets (ROA)-9.88%

Profit Margin-87.77%

EV/EBITDA-2.73

Beta1.31

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)59.82

Company Overview

Standard BioTools Inc. develops, manufactures, and sells instrumentation, consumables, and services for proteomics and genomics research. Their key platforms, including SomaScan, CyTOF, Hyperion, and Biomark X9, enable scientists to analyze proteins and genes for drug development and understanding disease mechanisms. The company serves academic institutions and biopharmaceutical companies globally.

P/B

0.89

Below book value

ROE

-13.1%

Net loss

Beta

1.31

Market Volatility

RSI(14)

59.8

Neutral zone

AI-generated summary. Not investment advice.